Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 2930 (2021)

Near real-time observation reveals increased prevalence of young patients in the ICU during the emerging third SARS-CoV-2 wave in Switzerland

DOI
https://doi.org/10.4414/smw.2021.20553
Cite this as:
Swiss Med Wkly. 2021;151:w20553
Published
21.07.2021

Summary

AIMS OF THE STUDY

During the ongoing COVID-19 pandemic, the launch of a large-scale vaccination campaign and virus mutations have hinted at possible changes in transmissibility and the virulence affecting disease progression up to critical illness, and carry potential for future vaccination failure. To monitor disease development over time with respect to critically ill COVID-19 patients, we report near real-time prospective observational data from the RISC-19-ICU registry that indicate changed characteristics of critically ill patients admitted to Swiss intensive care units (ICUs) at the onset of a third pandemic wave.

METHODS

1829 of 3344 critically ill COVID-19 patients enrolled in the international RISC-19-ICU registry as of 31 May 2021 were treated in Switzerland and were included in the present study. Of these, 1690 patients were admitted to the ICU before 1 February 2021 and were compared with 139 patients admitted during the emerging third pandemic wave

RESULTS

Third wave patients were a mean of 5.2 years (95% confidence interval [CI] 3.2–7.1) younger (median 66.0 years, interquartile range [IQR] 57.0–73.0 vs 62.0 years, IQR 54.5–68.0; p <0.0001) and had a higher body mass index than patients admitted in the previous pandemic period. They presented with lower SAPS II and APACHE II scores, less need for circulatory support and lower white blood cell counts at ICU admission. P/F ratio was similar, but a 14% increase in ventilatory ratio was observed over time (p = 0.03)

CONCLUSION

Near real-time registry data show that the latest COVID-19 patients admitted to ICUs in Switzerland at the onset of the third wave were on average 5 years younger, had a higher body mass index, and presented with lower physiological risk scores but a trend towards more severe lung failure. These differences may primarily be related to the ongoing nationwide vaccination campaign, but the possibility that changes in virus-host interactions may be a co-factor in the age shift and change in disease characteristics is cause for concern, and should be taken into account in the public health and vaccination strategy during the ongoing pandemic. (ClinicalTrials.gov Identifier: NCT04357275)

References

  1. Wendel Garcia PD, Fumeaux T, Guerci P, Heuberger DM, Montomoli J, Roche-Campo F, et al.; RISC-19-ICU Investigators. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine. 2020;25:100449. doi:.https://doi.org/10.1016/j.eclinm.2020.100449
  2. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60–73. doi:.https://doi.org/10.1007/s00134-020-06294-x
  3. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al., RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi:.https://doi.org/10.1056/NEJMoa2021436
  4. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al.; Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324(13):1317–29. doi:.https://doi.org/10.1001/jama.2020.17022
  5. Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al., INSPIRATION Investigators. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021;325(16):1620–30. doi:.https://doi.org/10.1001/jama.2021.4152
  6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15. doi:.https://doi.org/10.1056/NEJMoa2034577
  7. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16. doi:.https://doi.org/10.1056/NEJMoa2035389
  8. Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021;27(4):620–1. doi:.https://doi.org/10.1038/s41591-021-01270-4
  9. Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath polymerase chain reaction. J Infect Dis. 2021;223(10):1666–70. doi:.https://doi.org/10.1093/infdis/jiab082
  10. Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH ; CMMID COVID-19 Working Group. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593(7858):270–4. doi:.https://doi.org/10.1038/s41586-021-03426-1
  11. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7. doi:.https://doi.org/10.1016/S0140-6736(07)61602-X
  12. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization; 2020 [cited 2021 Jun 13]; Available from: https://apps.who.int/iris/handle/10665/331329.
  13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi:.https://doi.org/10.1016/j.jbi.2008.08.010
  14. Hilty MP, Wendel Garcia PD. hobbes8080/risc-19-icu: registry data transformation v1.0. Zenodo Data Repos. [Internet] 2020; Available from: https://zenodo.org/record/3757064.
  15. Federal Office of Public Health. COVID-19 epidemiological data key figures for Switzerland. Fed. Off. Public Health [Internet] 2021; Available from: https://www.covid19.admin.ch/de/epidemiologic/vacc-doses.
  16. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models using lme4. J Stat Softw. 2015;67(1). doi:.https://doi.org/10.18637/jss.v067.i01
  17. Baayen RH, Davidson DJ, Bates DM. Mixed-effects modeling with crossed random effects for subjects and items. J Mem Lang. 2008;59(4):390–412. doi:.https://doi.org/10.1016/j.jml.2007.12.005
  18. Barr DJ, Levy R, Scheepers C, Tily HJ. Random effects structure for confirmatory hypothesis testing: Keep it maximal. J Mem Lang. 2013;68(3):255–78. doi:.https://doi.org/10.1016/j.jml.2012.11.001
  19. R Development Core Team. R: A language and environment for statistical computing [Internet]. R Foundation for Statistical Computing, Vienna, Austria; 2011.Available from: http://www.R-project.org/.
  20. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. 1st ed. 2009. Corr. 3rd printing 2010 edition. New York: Springer; 2010.Available from: http://ggplot2.org.
  21. Favaron E, Ince C, Hilty MP, Ergin B, van der Zee P, Uz Z, et al. Capillary Leukocytes, Microaggregates, and the Response to Hypoxemia in the Microcirculation of Coronavirus Disease 2019 Patients. Crit Care Med. 2021;49(4):661–70. doi:.https://doi.org/10.1097/CCM.0000000000004862
  22. Bein T, Weber-Carstens S, Apfelbacher C. Long-term outcome after the acute respiratory distress syndrome: different from general critical illness? Curr Opin Crit Care. 2018;24(1):35–40. doi:.https://doi.org/10.1097/MCC.0000000000000476
  23. Gelman A, Hill J. Data Analysis Using Regression and Multilevel/Hierarchical Models [Internet]. Cambridge: Cambridge University Press; 2006 [cited 2021 June 15]. Available from: https://www.cambridge.org/core/books/data-analysis-using-regression-and-multilevelhierarchical-models/32A29531C7FD730C3A68951A17C9D983.

Most read articles by the same author(s)